These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274 [TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease and dyslipidemia: beyond LDL. Pöss J; Custodis F; Werner C; Weingärtner O; Böhm M; Laufs U Curr Pharm Des; 2011; 17(9):861-70. PubMed ID: 21418031 [TBL] [Abstract][Full Text] [Related]
5. High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases. Zhang Y; Luo S; Gao Y; Tong W; Sun S Angiology; 2024 May; 75(5):441-453. PubMed ID: 36788038 [TBL] [Abstract][Full Text] [Related]
6. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173 [TBL] [Abstract][Full Text] [Related]
7. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
8. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Lin Y; Mousa SS; Elshourbagy N; Mousa SA Vasc Health Risk Manag; 2010 Mar; 6():73-85. PubMed ID: 20234782 [TBL] [Abstract][Full Text] [Related]
9. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336 [TBL] [Abstract][Full Text] [Related]
11. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
12. Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk. Yanai H; Adachi H; Hakoshima M; Katsuyama H Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362288 [TBL] [Abstract][Full Text] [Related]
13. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366 [TBL] [Abstract][Full Text] [Related]
14. Statins and metabolism of high density lipoprotein. Sviridov D; Nestel P; Watts G Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):215-21. PubMed ID: 17630948 [TBL] [Abstract][Full Text] [Related]
15. Should we routinely measure low-density and high-density lipoprotein subclasses? Rizzo M; Berneis K; Zeljkovic A; Vekic J Clin Lab; 2009; 55(11-12):421-9. PubMed ID: 20225664 [TBL] [Abstract][Full Text] [Related]
16. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients. Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297 [TBL] [Abstract][Full Text] [Related]